# A Rare Presentation of T-cell Prolymphocytic Leukemia With Abnormal Uterine Bleeding

**Authors:** Zeinab Nasser, Sarine Tahmazian, Moneb Bughrara, Batoul Nasser, Aula Ramo, Vrushali Dabak

PMC · DOI: 10.14740/jh2152 · Journal of Hematology · 2026-01-04

## TL;DR

A 57-year-old woman with no prior health issues was diagnosed with a rare form of T-cell leukemia after presenting with unusual symptoms including abnormal uterine bleeding.

## Contribution

This case highlights a rare presentation of T-PLL with endometrial involvement and postmenopausal bleeding.

## Key findings

- The patient exhibited T-PLL with endometrial infiltration, which is uncommon.
- Abnormal uterine bleeding was linked to the presence of T-PLL in the endometrium.
- Alemtuzumab treatment was initiated following diagnosis.

## Abstract

T-cell prolymphocytic leukemia (T-PLL) is a rare and clinically aggressive T-cell neoplasm, which is composed of lymphoid cells that are of post-thymic T-cell origin. This is a case of a 57-year-old female with no significant medical history, who presented with a 4-month history of facial swelling, peripheral edema, dyspnea, palpitations, and abnormal uterine bleeding (AUB). A complete blood count demonstrated lymphocytosis, and a computed tomography (CT) scan of the abdomen and pelvis showed diffuse lymphadenopathy, splenomegaly, and uterine fibroids. A bone marrow biopsy confirmed the presence of T-PLL with a subsequent endometrial biopsy showing atypical lymphoid proliferation consistent with T-PLL. The patient was started on alemtuzumab for T-PLL treatment. This case demonstrates a rare presentation of T-PLL with endometrial involvement, which may have contributed to the patient’s postmenopausal uterine bleeding. Recognition and evaluation of disease infiltration require prompt clinical assessment to reduce the morbidity and mortality associated with T-PLL.

## Linked entities

- **Diseases:** T-cell prolymphocytic leukemia (MONDO:0019468)

## Full-text entities

- **Genes:** ATM (ATM serine/threonine kinase) [NCBI Gene 472] {aka AT1, ATA, ATC, ATD, ATDC, ATE}, CD2 (CD2 molecule) [NCBI Gene 914] {aka LFA-2, SRBC, T11}, MTCP1 (mature T cell proliferation 1) [NCBI Gene 4515] {aka P13MTCP1, TCL1C, p8MTCP1}, BCR (BCR activator of RhoGEF and GTPase) [NCBI Gene 613] {aka ALL, BCR1, CML, D22S11, D22S662, PHL}, RAD51D (RAD51 paralog D) [NCBI Gene 5892] {aka BROVCA4, R51H3, RAD51L3, TRAD}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, TCL1B (TCL1 family AKT coactivator B) [NCBI Gene 9623] {aka SYN-1, TML1}, HP (haptoglobin) [NCBI Gene 3240] {aka HP2ALPHA2, HPA1S}, CD52 (CD52 molecule) [NCBI Gene 1043] {aka CDW52, EDDM5, HE5}, TCL1A (TCL1 family AKT coactivator A) [NCBI Gene 8115] {aka TCL1}, CD7 (CD7 molecule) [NCBI Gene 924] {aka GP40, LEU-9, TP41, Tp40}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) [NCBI Gene 25] {aka ABL, BCR-ABL, CHDSKM, JTK7, bcr/abl, c-ABL}, CD5 (CD5 molecule) [NCBI Gene 921] {aka LEU1, T1}
- **Diseases:** EBV (MESH:D020031), skin involvement (MESH:D012871), CLL (MESH:D015451), cancer (MESH:D009369), CNS involvement (MESH:C538190), T-PLL (MESH:D015461), peripheral T-cell lymphoma (MESH:D016411), dyspnea (MESH:D004417), hepatosplenomegaly (MESH:C535727), B-PLL (MESH:D054403), edema (MESH:D004487), ATLL (MESH:D015459), skin infiltration (MESH:D017254), splenomegaly (MESH:D013163), CMV (MESH:D003586), bleeding (MESH:D006470), pleural effusion (MESH:D010996), lymphadenopathy (MESH:D008206), pneumonia (MESH:D011014), mature lymphocytic leukemias (MESH:D007945), fatigue (MESH:D005221), hematologic malignancies (MESH:D019337), fevers (MESH:D005334), acute blood loss (MESH:D000208), Sezary syndrome (MESH:D012751), bone marrow failure (MESH:D000080983), AUB (MESH:D014592), anemia (MESH:D000740), leukemia (MESH:D007938), death (MESH:D003643), CBC (MESH:D006402), COVID-19 (MESH:D000086382), thrombocytopenia (MESH:D013921), weight loss (MESH:D015431), extra nodal marginal zone lymphoma (MESH:D018442), abdominal distension (MESH:D000007), T-cell lymphoproliferative disorders (MESH:D008232), facial (MESH:D005153), fibroids (MESH:D007889), lymphomas (MESH:D008223), palpitations (MESH:D006331), tenderness (MESH:D063806), mature T-cell leukemia (MESH:D015458), hepatitis (MESH:D056486), lymphocytosis (MESH:D008218), T-cell neoplasm (MESH:D018307), diffuse large B-cell lymphoma (MESH:D016403)
- **Chemicals:** Alemtuzumab (MESH:D000074323), Iron (MESH:D007501), vitamin B12 (MESH:D014805), folate (MESH:D005492)
- **Species:** Human T-cell leukemia virus type I (no rank) [taxon 11908], Nicotiana tabacum (American tobacco, species) [taxon 4097], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12948471/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12948471/full.md

## References

7 references — full list in the complete paper: https://tomesphere.com/paper/PMC12948471/full.md

---
Source: https://tomesphere.com/paper/PMC12948471